View Older Stories View More Recent Stories

Nov 13, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
Nov 13, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
Nov 12, 2019 07:05AM Ionis Pharmaceuticals to present at upcoming investor conferences
Nov 6, 2019 07:00AM Ionis provides third quarter financial results and improved 2019 guidance
Nov 5, 2019 04:05PM Akcea Reports Financial Results and Highlights for Third Quarter 2019
Nov 5, 2019 04:05PM Akcea Reports Financial Results and Highlights for Third Quarter 2019
Nov 1, 2019 07:00AM Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
Nov 1, 2019 07:00AM Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
Oct 28, 2019 07:05AM Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
Oct 23, 2019 07:05AM Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences
Oct 23, 2019 07:00AM Akcea Announces Appointment of New Chief Commercial Officer
Oct 23, 2019 07:00AM Akcea Announces Appointment of New Chief Commercial Officer
Oct 22, 2019 07:05AM Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
Oct 22, 2019 07:00AM Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
Oct 22, 2019 07:00AM Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
Oct 10, 2019 07:05AM Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
Oct 9, 2019 06:52AM Ionis' (IONS) Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
Oct 9, 2019 06:50AM Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
Oct 7, 2019 06:51AM Akcea Therapeutics (AKCA), Pfizer (PFE) Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Oct 7, 2019 06:50AM Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Oct 7, 2019 06:50AM Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Oct 2, 2019 07:36AM Biogen (BIIB) Announces Landmark NURTURE Study of Infants with SMA Treated Pre-Symptomatically with SPINRAZA Published in Neuromuscular Disorders
Oct 2, 2019 07:30AM Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders
Sep 25, 2019 10:05AM Ionis to receive the CLSA's 2019 Pantheon DiNA™ Award for Company of the Year
Sep 23, 2019 07:12AM Akcea Therapeutics (AKCA) Reports Election of Michael J. Yang and Joseph ‘Skip’ Klein III to Board
Sep 23, 2019 07:00AM Akcea Announces CEO Transition and Elects Two New Board Members
Sep 18, 2019 07:34AM Biogen (BIIB) Reports Initiation of New Global Clinical Trial, DEVOTE, Evaluating Higher Dose of SPINRAZA (nusinersen) & Additional Data
Sep 18, 2019 07:30AM Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
Sep 18, 2019 07:30AM Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
Sep 16, 2019 07:02AM Akcea Therapeutics (AKCA) Reports Positive Phase 1 Results of AKCEA-TTR-LRx
Sep 16, 2019 07:00AM Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
Sep 16, 2019 07:00AM Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
Aug 29, 2019 07:00AM Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings
Aug 29, 2019 07:00AM Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings
Aug 28, 2019 07:05AM Ionis Pharmaceuticals to present at upcoming investor conferences
Aug 27, 2019 07:05AM Ionis licenses hepatitis B program to GSK
Aug 7, 2019 05:10PM New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
Aug 7, 2019 05:10PM New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
Aug 7, 2019 07:00AM Ionis Reports Second Quarter 2019 Financial Results
Aug 6, 2019 05:14PM Akcea Therapeutics (AKCA), Ionis (IONS) Announce BROADEN Study with WAYLIVRA in Patients with FPL Met its Primary Endpoint
Aug 6, 2019 04:05PM Akcea Reports Financial Results and Highlights for Second Quarter 2019
Aug 6, 2019 04:05PM Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy
Aug 6, 2019 04:05PM Akcea Reports Financial Results and Highlights for Second Quarter 2019
Aug 6, 2019 04:05PM Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy
Jul 30, 2019 07:05AM Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast
Jul 29, 2019 07:00AM Akcea Therapeutics to Hold Second Quarter 2019 Financial Results Webcast
Jul 29, 2019 07:00AM Akcea Therapeutics to Hold Second Quarter 2019 Financial Results Webcast
Jul 16, 2019 07:00AM hATTR Compass™ Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch
Jul 16, 2019 07:00AM hATTR Compass™ Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch
Jul 1, 2019 07:32AM Biogen (BIIB) Announces New Data Further Establishing SPINRAZA as Foundation of Care in SMA for Broad Range of Patients
View More Recent Stories View Older Stories